← Leaderboards
Horacio Kaufmann
Mount Sinai School Of Medicine Of Cuny
$10,533,467
Attributed
$12,800,768
Total exposure
13
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,750,990 · 10
FDA$3,049,778 · 3
By mechanism
R01$7,225,950 · 5
U01$3,632,800 · 1
U54$1,836,685 · 2
M01$85,333 · 4
R13$20,000 · 1
Top collaborators
- Cyndya Adriana Shibao4 shared
- Chang Yu4 shared
- Jose Alberto Palma Carazo3 shared
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchNatural HistoryMultiple System AtrophyNeurodegenerative DisordersProspectiveAlpha SynucleinAffectClinical TrialsNeuronsHuman SubjectRare DiseasesSynucleinopathyBiological MarkersProteinsDepositionNeuroimagingNerve DegenerationOutcome MeasureParkinson DiseaseCognition DisordersMotorAreaCognitiveCytoplasmic Inclusion
Grant awards (39)
Clinical Trial Readiness for Multiple System Atrophy - Resubmission - 1$1,344,579
U01 · FY2025 · NS · contact PI
Clinical Trial Readiness for Multiple System Atrophy$230,598
U01 · FY2024 · NS · contact PI
Clinical Trial Readiness for Multiple System Atrophy - Resubmission - 1$1,007,378
U01 · FY2023 · NS · contact PI
Clinical Trial Readiness for Multiple System Atrophy - Resubmission - 1$1,050,245
U01 · FY2022 · NS · contact PI
A futility trial of sirolimus in multiple system atrophy$781,753
R01 · FY2020 · NS · contact PI
A futility trial of sirolimus in multiple system atrophy$777,109
R01 · FY2019 · NS · contact PI
Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure IND117394 12/28/12$399,898
R01 · FY2019 · FD
A futility trial of sirolimus in multiple system atrophy$807,858
R01 · FY2018 · NS · contact PI
Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure IND117394 12/28/12$401,228
R01 · FY2018 · FD
Project 1: Longitudinal Observational Study of Autonomic Synucleinopathies$245,775
U54 · FY2018 · NS · contact PI
6th International Multiple System Atrophy Congress$20,000
R13 · FY2018 · NS · contact PI
Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure IND117394 12/28/12$396,930
R01 · FY2017 · FD
CARBIDOPA IN FAMILIAL DYSAUTONOMIA$370,022
R01 · FY2017 · FD · contact PI
Project 1: Longitudinal Observational Study of Autonomic Synucleinopathies$245,775
U54 · FY2017 · NS · contact PI
Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure IND117394 12/28/12$427,855
R01 · FY2016 · FD
CARBIDOPA IN FAMILIAL DYSAUTONOMIA$340,829
R01 · FY2016 · FD · contact PI
Project 1: Longitudinal Observational Study of Autonomic Synucleinopathies$245,775
U54 · FY2016 · NS · contact PI
CARBIDOPA IN FAMILIAL DYSAUTONOMIA$347,371
R01 · FY2015 · FD · contact PI
Project 1: Longitudinal Observational Study of Autonomic Synucleinopathies$260,025
U54 · FY2015 · NS · contact PI
project 1 - Autonomic Rare Diseases Clinical Research Consortium$170,614
U54 · FY2013 · NS · contact PI
project 1 - Autonomic Rare Diseases Clinical Research Consortium$134,261
U54 · FY2012 · NS · contact PI
project 1 - Autonomic Rare Diseases Clinical Research Consortium$172,338
U54 · FY2011 · NS · contact PI
project 1 - Autonomic Rare Diseases Clinical Research Consortium$190,889
U54 · FY2010 · NS · contact PI
Carbidopa for the treatment of nausea and vomiting in familial dysautonomiaIND #$167,132
R01 · FY2010 · FD · contact PI
Carbidopa for the treatment of nausea and vomiting in familial dysautonomiaIND #$198,513
R01 · FY2009 · FD · contact PI
project 1 - Autonomic Rare Diseases Clinical Research Consortium$171,233
U54 · FY2009 · NS · contact PI
OTOLITH INFLUENCES ON SYMPATHETIC ACTIVITY$374,907
R01 · FY2004 · DC
L-DOPS in Neurogenic Orthostatic Hypotension$37,158
M01 · FY2004 · RR
Effect of Sildenafil on Blood Pressure and Heart Rate in Pts. with Autonomic...$619
M01 · FY2004 · RR
OTOLITH INFLUENCES ON SYMPATHETIC ACTIVITY$364,338
R01 · FY2003 · DC
OTOLITH INFLUENCES ON SYMPATHETIC ACTIVITY$354,075
R01 · FY2002 · DC
L DOPS IN NEUROGENIC ORTHOSTATIC HYPOTENSION$0
M01 · FY2002 · RR
SILDENAFIL EFFECT ON BP/HR IN PRIMARY AUTONOMIC FAILURE$0
M01 · FY2002 · RR
OTOLITH INFLUENCES ON SYMPATHETIC ACTIVITY$344,273
R01 · FY2001 · DC
L DOPS IN NEUROGENIC ORTHOSTATIC HYPOTENSION$0
M01 · FY2001 · RR
SILDENAFIL EFFECT ON BP/HR IN PRIMARY AUTONOMIC FAILURE$0
M01 · FY2001 · RR
OTOLITH INFLUENCES ON SYMPATHETIC ACTIVITY$371,859
R01 · FY2000 · DC
L DOPS IN NEUROGENIC ORTHOSTATIC HYPOTENSION$47,556
M01 · FY2000 · RR
SILDENAFIL EFFECT ON BP/HR IN PRIMARY AUTONOMIC FAILURE$0
M01 · FY2000 · RR